Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
Tuesday, August 29, 2023Lantern Pharma Inc an artificial intelligence AI company developing targeted and transformative cancer therapies using its proprietary AI and machine learning ML platform RADR with multiple clinical stage drug programs
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
Tuesday, August 29, 2023Faron Pharmaceuticals Ltd a clinicalstage biopharmaceutical company focused on tackling cancers via novel immunotherapies today announces the US Food and Drug Administration FDA has granted
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Tuesday, August 29, 2023Sandoz a global leader in generic and biosimilar medicines today announced that the US Food and Drug Administration FDA has approved its biosimilar Tyruko natalizumabsztn developed by Polpharma Biologics Tyruko is approved to treat all indications co...
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
Friday, August 25, 2023Radiopharm Theranostics a developer of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce an expanded agreement with TerThera to supply
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
Thursday, August 24, 2023GRI Bio Inc NASDAQ GRI GRI Bio or the Company a biotechnology company advancing an innovative pipeline of Natural Killer T NKT cell modulators for the treatment of inflammatory fibrotic and autoimmune diseases today announced that the Company has ent...
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
Thursday, August 24, 2023Regeneron Pharmaceuticals Inc today announced that the Biomedical Advanced Research and Development Authority BARDA has entered into an agreement with Regeneron to support clinical development clinical manufacturing
Oxford Biomedica expands agreement with Cabaletta Bio; adding new viral vector programme for CD19-CAR T therapies
Thursday, August 24, 2023Oxford Biomedica plc LSEOXB Oxford Biomedica or the Company a quality and innovationled viral vector CDMO today announces that it has expanded its License and Supply Agreement LSA with Cabaletta Bio Inc Nasdaq CABA Cabaletta Bio a Philadelphiabased c...
Transnetyx Expands Offering with Genetic Sequencing Through Acquisition of Laragen
Wednesday, August 23, 2023Transnetyx a global leader in outsourced genetic services announced the acquisition of Laragen a sequencing and genetic services company in Culver City CA The addition of Sanger sequencing and nextgeneration sequencing NGS services to the Transnetyx...
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
Tuesday, August 22, 2023Anebulo Pharmaceuticals Inc Nasdaq ANEB the Company or Anebulo a clinicalstage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ACI and substance abuse today announced positive feedback fro...
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Tuesday, August 22, 2023Skye Bioscience Inc OTCQB SKYE Skye or the Company announced that it has undertaken a strategic initiative that expands the Companys resources and technologies focused on developing therapeutic products focused on the endocannabinoid system ECS
